Topical Nano Clove/Thyme Gel against Genetically Identified Clinical Skin Isolates: In Vivo Targeting Behavioral Alteration and IGF-1/pFOXO-1/PPAR γ Cues

Molecules. 2021 Sep 15;26(18):5608. doi: 10.3390/molecules26185608.

Abstract

Antimicrobial resistance is a dramatic global threat; however, the slow progress of new antibiotic development has impeded the identification of viable alternative strategies. Natural antioxidant-based antibacterial approaches may provide potent therapeutic abilities to effectively block resistance microbes' pathways. While essential oils (EOs) have been reported as antimicrobial agents, its application is still limited ascribed to its low solubility and stability characters; additionally, the related biomolecular mechanisms are not fully understood. Hence, the study aimed to develop a nano-gel natural preparation with multiple molecular mechanisms that could combat bacterial resistance in an acne vulgaris model. A nano-emulgel of thyme/clove EOs (NEG8) was designed, standardized, and its antimicrobial activity was screened in vitro and in vivo against genetically identified skin bacterial clinical isolates (Pseudomonas stutzeri, Enterococcus faecium and Bacillus thuringiensis). As per our findings, NEG8 exhibited bacteriostatic and potent biofilm inhibition activities. An in vivo model was also established using the commercially available therapeutic, adapalene in contra genetically identified microorganism. Improvement in rat behavior was reported for the first time and NEG8 abated the dermal contents/protein expression of IGF-1, TGF-β/collagen, Wnt/β-catenin, JAK2/STAT-3, NE, 5-HT, and the inflammatory markers; p(Ser536) NF-κBp65, TLR-2, and IL-6. Moreover, the level of dopamine, protective anti-inflammatory cytokine, IL-10 and PPAR-γ protein were enhanced, also the skin histological structures were improved. Thus, NEG8 could be a future potential topical clinical alternate to synthetic agents, with dual merit mechanism as bacteriostatic antibiotic action and non-antibiotic microbial pathway inhibitor.

Keywords: Bacillus thuringiensis; Enterococcus faecium; IGF-1; PPAR γ; Pseudomonas stutzeri; antibiotic; clinical bacterial isolate; clove; essential oil; nanogel; non-antibiotic; skin infection; thyme.

MeSH terms

  • Acne Vulgaris / drug therapy*
  • Animals
  • Anti-Bacterial Agents / chemistry
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Inflammatory Agents / chemistry
  • Anti-Inflammatory Agents / pharmacology*
  • Anti-Inflammatory Agents / therapeutic use
  • Behavior, Animal / drug effects*
  • Biofilms / drug effects
  • Cues
  • Forkhead Transcription Factors / metabolism
  • Insulin-Like Growth Factor I / metabolism
  • Interleukin-6 / metabolism
  • NF-kappa B / metabolism
  • Nanogels / chemistry
  • Nanogels / therapeutic use
  • PPAR gamma / metabolism
  • Plant Extracts / chemistry
  • Plant Extracts / pharmacology*
  • Plant Extracts / therapeutic use
  • Polyethylene Glycols / chemistry
  • Polyethylene Glycols / pharmacology*
  • Polyethylene Glycols / therapeutic use
  • Polyethyleneimine / chemistry
  • Polyethyleneimine / pharmacology*
  • Polyethyleneimine / therapeutic use
  • Rats
  • Skin / drug effects*
  • Skin / metabolism
  • Syzygium / chemistry
  • Thymus Plant / chemistry
  • Toll-Like Receptor 2 / metabolism
  • Transforming Growth Factor beta / metabolism
  • Wnt Proteins / metabolism

Substances

  • Anti-Bacterial Agents
  • Anti-Inflammatory Agents
  • Forkhead Transcription Factors
  • Interleukin-6
  • NF-kappa B
  • Nanogels
  • PPAR gamma
  • Plant Extracts
  • Toll-Like Receptor 2
  • Transforming Growth Factor beta
  • Wnt Proteins
  • polyethylene glycol polyethyleneimine nanogel
  • Polyethylene Glycols
  • Insulin-Like Growth Factor I
  • Polyethyleneimine